Greece Considers Reforms to Boost Clinical Research and Medical Access
Greece Considers Reforms to Boost Clinical Research and Medical Access
As of April 2026, Greece is positioning itself as a rising hub for clinical research.
The Ministry of Health has implemented bold reforms, such as the January Ministerial Decision, aimed at stripping away the bureaucratic red tape that has historically hindered progress.
By introducing standardized contracts, digitizing the process through the Mitos national registry, and enforcing strict timelines, the government is streamlining how clinical trials operate.
A new โฌ50 million Pharmaceutical Innovation Fund further bolsters this mission by bridging the gap to advanced medicine before full reimbursement.
Industry stakeholders, including the Hellenic Association of Pharmaceutical Companies, highlight that persistent fiscal pressures and the contentious "clawback" system continue to strain the relationship between the state and private developers.
While the move toward an EU-aligned, digital framework is a significant victory for modernization, the long-term success of these initiatives depends on whether Greece can balance effective cost-control with an environment that truly encourages R&D investment.
For Greece, it is a critical test of whether modernization can overcome systemic financial challenges.
